One member asked whether anyone else was tired of seeing patients with complications coming out of medspas, or whether it was a Miami problem. The answers came from everywhere, Connecticut included.
A Florida physician noted the state's new Prescription Drug Oversight Act, then shared a medspa owned by a nurse anesthetist that is now marketing stem cell therapy directly to consumers, with no physician oversight, no trial framework and no outcome tracking.
The medspa market has grown past $20 billion with minimal physician oversight. What started with Botox and fillers now includes hormone pellets, IV therapy, peptide injections, exosomes and stem cells, often sold at the edge of, or beyond, scope of practice. Regulators are starting to respond, with state laws, FDA action against grey-market peptide sellers and warning letters to compounders. But the demand is real: patients want prevention and optimization, and they are getting it from the wrong places.
The quote of the week, from a member's essay on the peptide market: the next phase will move either deeper into the shadows or back into accountable medicine.
Key takeaways
- Patient demand for longevity care is real; the gap is clinical infrastructure.
- Expect to manage complications, distrust and unrealistic expectations from medspa care.
- Regulation helps, but trained, credentialed physicians offering a better alternative is what closes the gap.
From Buzz in the chat, the longevitydocs™ Sunday newsletter, March 8, 2026. Member discussion, not clinical guidance.
Originally published in The Longevity Medicine Intelligence newsletter.
